-
A New Device for Early Detection of Breast Disease: Stakeholders Perspective Analysis in Brazil/LATAM/LMIC
Mar 10, 2025, 14:00 PM -
Health and Economic Value of Pneumococcal Conjugate Vaccine Against Antimicrobial Resistance in Brazil: An Agent-based Simulation Study
Mar 10, 2025, 14:00 PM -
Demonstrating Broader Economic Impact of Oncology Diagnostics and Therapeutics on Healthcare Resource Utilization Across All Relevant Specialties
Mar 10, 2025, 14:00 PM -
Epidemiology, Healthcare Resource Utilization, and Costs of Unresectable Locally Advanced or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma in China
Mar 10, 2025, 14:00 PM -
Healthcare Resource Utilization in Patients with Type 1 Diabetes with or without Prior Type 2 Diabetes Misdiagnosis: A Study in a U.S. Managed Care Population
Mar 10, 2025, 14:00 PM -
Evaluating the Cost-Effectiveness of Wastewater-Based Disease Surveillance
Mar 10, 2025, 14:00 PM -
Group-Based Trajectory Modeling to Identify Longitudinal Patterns of Adherence to Statins in Older Adults on Concomitant Triple Therapy (Oral Antidiabetic, RAS Antagonists, Statins)
Mar 10, 2025, 14:00 PM -
Systematic Evaluation of Bone Health Dynamics Associated With GLP-1 Receptor Agonists in Type 2 Diabetes Patients: Fracture Risk and Osteoporotic Complications
Mar 10, 2025, 14:00 PM -
Unlocking the Potential of Radiology Reports Using NLP: A Real-World Data Approach to Rotator Cuff Tear Severity
Mar 10, 2025, 14:00 PM -
Selection and Stability of Parametric Bivariate Copula Models for Joint Modelling of Overall and Progression-Free Survival
Mar 10, 2025, 14:00 PM -
Racial and Health Insurance Status Disparities in the Use of Percutaneous Vertebral Augmentation and Healthcare Utilization for Osteoporotic Vertebral Fractures: A Retrospective Observational Analysis
Mar 10, 2025, 14:00 PM -
Impact of a Digital Musculoskeletal Program on Healthcare Spending Among Participants with Chronic Musculoskeletal Pain and Comorbidities
Mar 10, 2025, 14:00 PM -
Matching-Adjusted Indirect Comparisons (MAIC) of TAR-200 vs FDA Approved Novel Agents in Bacillus Calmette-Guerin (BCG) Unresponsive High-Risk (HR) Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in Situ (CIS)
Mar 10, 2025, 14:00 PM -
From Data to Actionable Insight: A Collaborative Monitoring & Evaluation (M&E) Initiative Convened by Canada’s Drug Agency (CDA-AMC) - Piloting Plans for Diabetes and Contraception
Mar 10, 2025, 14:00 PM -
Study on Online Tools of Pharmacoeconomic Model Construction and Value Communication
Mar 10, 2025, 14:00 PM -
Costs of Care for Patients With Triple Negative Metastatic Breast Cancer: A Retrospective US Claims Data Study
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness Analysis of NALIRIFOX as First-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in Japan
Mar 10, 2025, 14:00 PM -
Examining Patterns in Breast Cancer Patient Characteristics and Treatment Throughout the COVID-19 Pandemic
Mar 10, 2025, 14:00 PM -
Real-World Events Often Associated with Relapse (EOAR) Rates Among Patients with Multiple Sclerosis on Natalizumab Using Claims Data from the PearlDiver Mariner Database
Mar 10, 2025, 14:00 PM -
ICER Thresholds in Cost-Utility Analysis: Assessing Conceptual Relevance and Practical Adequacy for Drug Reimbursement Decision-Making in The US
Mar 10, 2025, 14:00 PM
